ChiaChi Hu

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Kim Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology · 2015 · 669 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

C. Paul, Jennifer Clay Cather, Melinda Gooderham et al. · British Journal of Dermatology · 2015 · 479 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino et al. · Annals of the Rheumatic Diseases · 2014 · 441 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial

Kim Papp, Jennifer Clay Cather, Les Rosoph et al. · The Lancet · 2012 · 280 citations

Medicine, Dermatology, Pharmacotherapy +6

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann et al. · The Journal of Rheumatology · 2016 · 210 citations

Medicine, Internal Medicine, Pharmacotherapy +15